NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
12.71
Dollar change
+0.13
Percentage change
1.03
%
IndexRUT P/E73.60 EPS (ttm)0.17 Insider Own36.77% Shs Outstand78.43M Perf Week-8.03%
Market Cap1.00B Forward P/E53.06 EPS next Y0.24 Insider Trans0.00% Shs Float49.81M Perf Month7.89%
Enterprise Value949.06M PEG1.50 EPS next Q0.01 Inst Own31.93% Short Float6.57% Perf Quarter79.52%
Income14.11M P/S9.28 EPS this Y25.10% Inst Trans12.15% Short Ratio3.47 Perf Half Y133.21%
Sales107.92M P/B18.01 EPS next Y74.08% ROA20.83% Short Interest3.27M Perf YTD139.59%
Book/sh0.71 P/C18.00 EPS next 5Y48.97% ROE33.47% 52W High14.69 -13.48% Perf Year372.49%
Cash/sh0.71 P/FCF51.34 EPS past 3/5Y- - ROIC24.35% 52W Low2.40 428.48% Perf 3Y610.06%
Dividend Est.- EV/EBITDA57.10 Sales past 3/5Y13.87% 16.56% Gross Margin62.51% Volatility7.02% 5.65% Perf 5Y192.18%
Dividend TTM- EV/Sales8.79 EPS Y/Y TTM489.15% Oper. Margin14.20% ATR (14)0.73 Perf 10Y236.24%
Dividend Ex-Date- Quick Ratio3.12 Sales Y/Y TTM29.77% Profit Margin13.07% RSI (14)50.23 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio3.66 EPS Q/Q1035.38% SMA20-5.93% Beta2.17 Target Price14.90
Payout0.00% Debt/Eq0.06 Sales Q/Q37.59% SMA5014.34% Rel Volume0.77 Prev Close12.58
Employees104 LT Debt/Eq0.05 EarningsMay 07 AMC SMA20079.27% Avg Volume942.72K Price12.71
IPOJun 24, 2008 Option/ShortYes / Yes EPS/Sales Surpr.264.50% 12.58% Trades Volume727,210 Change1.03%
Date Action Analyst Rating Change Price Target Change
May-27-25Initiated Canaccord Genuity Buy $13
Aug-16-22Downgrade Oppenheimer Outperform → Perform
Aug-11-22Downgrade B. Riley Securities Buy → Neutral $6 → $2.40
Mar-08-22Initiated ROTH Capital Buy $7
Oct-16-19Initiated Oppenheimer Outperform $6
Feb-14-19Initiated B. Riley FBR Buy $7
Nov-27-17Resumed H.C. Wainwright Buy $6 → $8
Sep-25-17Initiated Ladenburg Thalmann Buy $7
Jan-03-17Initiated Rodman & Renshaw Buy $6
Jun-20-25 08:32AM
Jun-11-25 08:31AM
Jun-09-25 08:32AM
Jun-04-25 08:32AM
May-08-25 03:26AM
06:00PM Loading…
May-07-25 06:00PM
04:02PM
May-05-25 08:32AM
Apr-29-25 08:32AM
Apr-28-25 08:34AM
Apr-07-25 10:32PM
Mar-20-25 08:34AM
Mar-19-25 08:34AM
Mar-13-25 08:34AM
Mar-11-25 04:04PM
11:11AM Loading…
Mar-05-25 11:11AM
02:10AM
Mar-04-25 05:15PM
04:13PM
04:02PM
Mar-03-25 07:14AM
Feb-25-25 04:07PM
Jan-06-25 08:32AM
Dec-03-24 08:34AM
Nov-22-24 09:15AM
Nov-14-24 08:32AM
Nov-08-24 12:00PM
Nov-07-24 08:32AM
Nov-05-24 09:15AM
Nov-01-24 11:02AM
05:15PM Loading…
Oct-31-24 05:15PM
04:09PM
04:04PM
Oct-30-24 09:20AM
Oct-28-24 08:32AM
Oct-24-24 08:32AM
Oct-23-24 08:34AM
Oct-18-24 09:40AM
Oct-15-24 08:32AM
Oct-09-24 05:18PM
Sep-26-24 04:12PM
09:40AM
Sep-20-24 08:32AM
Sep-10-24 08:32AM
Sep-09-24 08:34AM
Aug-23-24 08:34AM
Aug-19-24 08:32AM
Aug-07-24 06:25PM
05:25PM
04:04PM
Aug-05-24 08:32AM
Jul-24-24 08:34AM
Jul-23-24 08:32AM
Jul-22-24 08:34AM
Jul-16-24 08:34AM
Jul-01-24 08:32AM
Jun-24-24 08:32AM
Jun-13-24 08:32AM
Jun-10-24 09:45AM
Jun-07-24 08:34AM
Jun-04-24 08:32AM
May-23-24 08:34AM
May-22-24 08:32AM
May-10-24 03:22PM
May-09-24 02:34PM
07:17AM
03:42AM
May-08-24 08:58PM
05:04PM
04:04PM
Apr-30-24 08:32AM
Apr-25-24 08:34AM
Apr-24-24 08:34AM
Apr-23-24 08:32AM
Mar-26-24 08:32AM
Mar-07-24 01:59PM
10:37AM
06:27AM
Mar-06-24 09:53PM
04:04PM
Feb-21-24 08:32AM
Feb-05-24 08:32AM
Jan-26-24 04:08PM
Dec-20-23 09:04AM
Dec-12-23 10:30AM
Nov-30-23 08:34AM
Nov-15-23 08:32AM
Nov-10-23 12:54PM
Nov-09-23 08:32AM
Nov-08-23 06:33PM
04:48PM
04:02PM
Nov-01-23 08:34AM
Oct-31-23 08:34AM
Oct-26-23 08:32AM
Oct-02-23 08:32AM
Aug-24-23 08:32AM
Aug-12-23 09:04AM
Aug-10-23 10:38AM
Aug-09-23 05:40PM
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fried Robert NChief Executive OfficerApr 09 '25Option Exercise3.3066,667220,0011,038,981Apr 09 07:52 PM
Lopez Carlos LuisSVP, General CounselMar 07 '25Buy7.862732,1462,251Mar 10 08:11 AM
Jaksch Frank L JrDirectorDec 13 '24Option Exercise3.6650,001183,004281,340Dec 13 07:12 PM
Jaksch Frank L JrDirectorDec 13 '24Sale6.1937,161229,956244,179Dec 13 07:12 PM
Frank Jaksch Jr.affiliateDec 13 '24Proposed Sale6.1937,161229,961Dec 13 01:54 PM
Pamir OzanChief Financial OfficerNov 22 '24Buy7.362,90721,3972,907Nov 25 07:28 AM
Patrick KristinDirectorAug 23 '24Option Exercise1.6723,00038,32023,000Aug 26 07:06 PM
Patrick KristinDirectorAug 23 '24Sale3.5723,00082,1100Aug 26 07:06 PM
Kristin PatrickaffiliateAug 23 '24Proposed Sale3.6923,00084,810Aug 23 11:52 AM